Inclusion Criteria:

• Male and Female outpatients at least 18 years of age who have previously participated in a Lilly sponsored neuroscience duloxetine clinical trial
• All females must have a negative urine pregnancy test at visit 1. Females of childbearing potential must agree to utilize medically acceptable and reliable means of birth control.
• Must sign the informed consent document

Exclusion Criteria:

• Have received treatment within the last 30 days with a drug except for duloxetine that has not received regulatory approval for any indication at the time of study entry
• In the opinion of the investigator, patient judged to be at serious suicidal risk.
• Serious or unstable hepatic or renal function or unstable narrow angle glaucoma.
• Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to visit 1 or potential to use a MAOI during the study or within 5 days of discontinuation of study drug.
• Any patient who previously experienced a serious adverse event while taking duloxetine unless approved by the Lilly Physician